参附注射液合重组人促红细胞生成素治疗肺癌贫血30例

Shenfu Injection Combined with Recombinant Human Erythropoietin in Treating 30 Cases of Lung Cancer Associated Anemia

目的观察参附注射液合重组人促红细胞生成素治疗肺癌贫血的疗效。方法将60例非小细胞肺癌贫血患者随机分为参附注射液联合重组人促红细胞生成素组(A组)30例,重组人促红细胞生成素组(B组)30例,观察2组患者的贫血改善、化疗完成、输血、中医症状评分、体能状态评分的变化。结果治疗后A组输血治疗率降低,血红蛋白上升,中医症状、体能状态改善,与B组比较,差异具有统计学意义(P<0.05)。结论参附注射液联合重组人促红细胞生成素治疗肺癌贫血有较好的疗效。

Objective To observe the effect of Shenfu injection （SI） plus Recombinant Human Erythropoietin （r-HuEPO） on lung cancer associated anemia. Methods 60 nonsmall-cell lung cancer patients with anemia were assigned randomly to SI plus r-HuEPO group （group A, n=30） and r-HuEPO group （group B, n =30）. The changes of rates of blood transfusion and postponing chemotherapy, TCM symptoms score and physical status score of two groups were compared. Results The rate of blood transfusion was reduced in group A after treatment, the increasing amphtude of hemoglobin in group A was higher significantly than that of group B, the improvement of TCM symptoms and physical status in group A was superior to that of group B after treatment respectively, and there were significant differences between them （P〈0.05）. Conclusion Shenfu injection combined with r-HuEPO have good effects on lung cancer associated anemia.